Orforglipron Phase 3 Trial for Obesity, Overweight Completes Primary Endpoint

The Phase 3 ATTAIN-MAINTAIN study (NCT06584916) investigating orforglipron for the maintenance of body weight reduction in participants with obesity or overweight completed its primary endpoint on 2025-11-21. This milestone indicates the completion of the main observation period for all participants in the trial.

Background

Obesity and overweight are chronic conditions associated with numerous health complications. Effective long-term weight management often requires strategies not only for initial weight loss but also for the crucial maintenance of that reduction. The ATTAIN-MAINTAIN study specifically evaluates orforglipron for its efficacy and safety in sustaining body weight reduction in individuals who have obesity or are overweight with weight-related comorbidities.

Trial design

The ATTAIN-MAINTAIN study (NCT06584916) is a Phase 3 clinical trial. It enrolled 376 participants diagnosed with obesity or who were overweight with weight-related comorbidities. The study's main purpose is to evaluate the efficacy and safety of orforglipron on the maintenance of body weight reduction. Participants in the trial received either orforglipron or a placebo as interventions.

What this means

The primary completion of the Phase 3 ATTAIN-MAINTAIN trial for orforglipron is a significant step in the drug development process. It signifies that all participants have completed the designated primary observation period, allowing for the collection of comprehensive data. The next stages will involve the analysis of this data to determine orforglipron's efficacy and safety profile for the maintenance of body weight reduction. The eventual results will be crucial for understanding its potential role in addressing the long-term challenges of obesity and overweight management.

Source

The information regarding the primary completion of this trial was obtained from ClinicalTrials.gov, a public database of clinical studies. The update for study NCT06584916, titled "A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN)," was posted on 2025-11-21 on clinicaltrials.gov.